Charles River Laboratories Acquires Agilux Laboratories, Inc.
Oct 19 2016
Charles River has announced the acquisition of Agilux Laboratories, Inc., a Worcester, Massachusetts-based contract research organization (CRO) providing a suite of integrated discovery small- and large-molecule bioanalytical services, DMPK (drug metabolism and pharmacokinetics) and pharmacology services. Agilux has built an enviable reputation for flexibility and speed, offering in vivo PK (pharmacokinetics), in vitro ADME (absorption, distribution, metabolism and excretion), in vivo pharmacology and bioanalysis to support drug discovery. They have also established themselves as a leading bioanalytical laboratory supporting preclinical and clinical programs.
With this acquisition, Charles River adds new and expanded scientific proficiencies to support your research needs from target identification and validation through preclinical development. We believe that Agilux’s unique combination of early-stage services, coupled with Charles River’s existing discovery and safety assessment capabilities, will greatly enhance the speed and efficiency of your lead identification, optimization and candidate selection efforts. Charles River and Agilux’s shared values of scientific expertise and exceptional customer service brings immediate value to our combined clients.
Read the press release »